Many of us are mindful about eating nutritious foods, but did you know that pairing certain foods together can actually boost the body’s ability to absorb their nutrients and amplify their health benefits?
Blog
-
New antibody drug conjugates can transform early HER2-positive breast cancer treatment
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents-antibody-drug conjugates (ADCs)-can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.
The results from the phase III DESTINY-Breast05 and DESTINY-Breast11 trials, presented in a Presidential Symposium, mark a paradigm shift in breast cancer treatment, positioning ADCs not only as powerful therapeutic agents when the disease has already progressed but also as potential new standards of care in patients with early disease.
There is a particular need for therapies to ensure patients with HER2-positive early breast cancer achieve pathological complete response following neoadjuvant therapies-i.e., delivered before surgery-, and a high unmet need to treat residual disease in those who do not, to prevent the development of metastasis.”
Dr. Evandro de Azambuja from the Jules Bordet Institute, Brussels, Belgium
Currently, trastuzumab emtansine (T-DM1) is the only ADC approved for patients with HER2-positive early breast cancer who show residual invasive disease after neoadjuvant therapy and are at a high risk of recurrence. In the DESTINY-Breast05, Trastuzumab deruxtecan (T-DXd), a new-generation ADC delivering a topoisomerase I inhibitor, showed to improve invasive disease-free survival and disease-free survival by 53% compared with T-DM1 (for both: hazard ratio [HR] 0.47; 95% confidence interval [CI] 0.34–0.66; p<0.0001). Also, T-DXd confirmed its high brain activity, demonstrating a clinically meaningful improvement in brain metastasis-free interval over T-DM1 (HR 0.64; 95% CI 0.35–1.17).
“The generally manageable safety profile and the superior efficacy data suggest that T-DXd should replace T-DM1 as the new standard of care for patients with HER2-positive, residual invasive breast cancer after neoadjuvant therapy,” notes de Azambuja.
The use of T-DXd also showed impressive findings earlier in the treatment pathway- before surgery- as reported in the DESTINY-Breast11 trial where 927 untreated patients with high-risk HER2-positive early breast cancer received either the ADC followed by standard HER2-targeted therapy (THP) or the conventional anthracycline-based regimen (ddAC-THP). The cycles of T-DXd, sequenced with THP, led to a significant increase in the rate of pathological complete response at surgery (67.3% versus 56.3%; p=0.003). “The T-DXd regimen has also the added advantage of an improved safety profile compared with the anthracycline-containing regimen,” comments de Azambuja noting the relevant reduction in cardiac toxicities which was observed with the ADC compared with the conventional treatment.
“In conjunction, these two studies establish T-DXd as a critical treatment option for early-stage HER2-positive breast cancer, ultimately providing a new tool for treatment tailoring for what was once considered the most aggressive subtype of breast cancer, and which today represents the one with the highest chance of cure,” highlights Dr Paolo Tarantino from the Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
After having reshaped the treatment of multiple types of metastatic cancers over the last few years, novel ADCs such as T-DXd are now “raising the bar” in the curative setting due to innovations in their design and mechanism of action. However, their use presents new challenges that need to be addressed. “For instance,
toxicity profiles must be carefully defined and substantial effort to prevent permanent or fatal toxicities is required. Dosing, duration and sequencing of ADCs must also be optimised to achieve maximal efficacy with the least side-effects, and equally critical is the identification of predictive biomarkers that may allow better tailoring of ADC therapy and minimise overtreatment,” clarifies Tarantino.
The presentation of the DESTINY-Breast05 and DESTINY-Breast11 trials results at the ESMO Congress 2025 cements the event’s role as a catalyst for global oncology progress. With ADCs now demonstrating superiority in both pre- and post-surgical settings, the oncology community stands at the threshold of a new chapter-one defined by smarter targeting, earlier intervention and deeper biological understanding.
“Besides the immediate practical impact, in fact, data presented today are expected to have a broader impact on the future of ADC research, marking the formal entrance of the new generation of drugs in the curative arena. This is a therapeutic strategy with tremendous potential, which we are only just starting to unleash, promising to reduce rates of recurrence and improve survival across multiple cancers in the years to come,” concludes Tarantino.
Source:
European Society for Medical Oncology
Continue Reading
-
Egypt’s Pyramids claim CAF Super Cup with 1-0 win over Morocco’s Berkane-Xinhua
CAIRO, Oct. 18 (Xinhua) — Egypt’s Pyramids Football Club captured its maiden CAF Super Cup title on Saturday, after edging Morocco’s Renaissance Berkane 1-0 at Cairo’s 30 June Stadium.
The breakthrough came in the 75th minute when Congolese…
Continue Reading
-
Antarctic meltwater accelerates Southern Ocean evolution under projected atmospheric warming – ESS Open Archive
- Antarctic meltwater accelerates Southern Ocean evolution under projected atmospheric warming ESS Open Archive
- Antarctica’s Ice Dwindles at Alarming Rate Mena FN
- What’s Going On With Antarctica’s Glaciers? InsideHook
- Damage development on…
Continue Reading
-
PlayStation’s early Black Friday offers: Gotham Knights, Suicide Squad and EA Sports PGA Tour now for $7 each
With Black Friday and Cyber Monday right around the corner, Sony has jumped early on the deals bandwagon. According to Comicbook.com, the company is offering three major PS5 games for just $7 each on the PlayStation Store.
Reportedly, this is a…
Continue Reading
-
What Do Surging Innodata Shares Signal After Recent Nasdaq 100 Inclusion in 2025?
If you’re eyeing Innodata stock and wondering whether it deserves a spot in your portfolio, you’re not alone. This is a company that’s made headlines for its meteoric rise. In just the past year, Innodata shares have soared an astonishing 322.6%, and the gains grow even more jaw-dropping when looking further back: over 2,000% in three years and nearly 2,900% across the past five. While the last week saw a minor dip of -4.6%, the stock was up 18.7% in the last month and is already up over 100% for 2024 so far. Clearly, there’s serious excitement (and some volatility) surrounding Innodata among investors and traders.
Behind some of these moves are broader market trends and investor enthusiasm for companies driving digital transformation, a space where Innodata has steadily carved out a recognized position. The impressive long-term rally suggests there’s been a major shift in how the market views Innodata’s growth prospects and risk, from an under-the-radar play to a company many now see as a winner in AI-driven data services.
But has the stock’s explosive run made it expensive, or is there still value hiding under the hood? According to our valuation ‘scorecard,’ Innodata is currently considered undervalued in 0 out of 6 widely-followed valuation checks, giving it a score of 0. That might raise some eyebrows after such a strong advance, but a number alone doesn’t tell the whole story.
Let’s walk through the major valuation approaches analysts use for companies like Innodata, and see what each one reveals. And stick around, because at the end, I’ll share a more insightful way to understand if the market is pricing Innodata right.
Innodata scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
The Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting its future free cash flows and discounting them back to today’s dollars. This approach helps investors understand what a business is fundamentally worth based on the cash it is expected to generate in the years ahead.
For Innodata, the starting point is its latest reported Free Cash Flow (FCF) of $32.58 million. Analyst forecasts see FCF moderating to $26.04 million by the end of 2026, with slight declines projected through 2035. While analysts provide estimates for up to five years, further projections are extrapolated and indicate generally flat to mildly decreasing cash flows into the next decade.
Simply Wall St’s two-stage DCF calculation arrives at an intrinsic value of $16.42 per share. With the company’s current share price well above this estimate, the implied discount suggests Innodata stock is a hefty 383.8% overvalued by this method.
Continue Reading
-
A Fresh Look at Electronic Arts (EA) Valuation After Recent Share Price Climb
Electronic Arts (EA) shares have drawn attention lately, especially after a steady climb over the past month. Investors are watching closely to see if the company can sustain this upward momentum.
See our latest analysis for Electronic Arts.
After a breakout month, Electronic Arts is capturing renewed investor interest. The stock’s 15.4% share price return over the past 30 days helped push its year-to-date gain to 37.3%. Momentum is clearly building, with strong gains reflected in a one-year total shareholder return of 39.5% and nearly 63% over the last three years.
If gaming’s rally has you thinking bigger, now is an ideal moment to broaden your search and discover See the full list for free.
With such impressive momentum, investors may wonder if Electronic Arts is still trading at an attractive valuation, or if the market has already factored in all of its future growth potential. Is there a genuine buying opportunity here, or is everything now reflected in the price?
Electronic Arts’ current share price sits slightly above the narrative’s fair value estimate, reflecting only a narrow gap between price and fundamentals. The market appears to have already factored in much of the anticipated future growth, making this a close call for value-oriented investors.
EA’s strategic focus on expanding live services and new game launches, such as Skate and Battlefield, is expected to drive revenue growth and foster player engagement. The relaunch of American Football and continued success of FC Mobile, particularly in fast-growing markets, are expected to significantly boost net bookings and player base.
Read the complete narrative.
What is behind this lofty price? The narrative hinges on ambitious projections for future earnings, margin expansion, and blockbuster product launches. Curious which assumptions fuel such a high bar for growth and whether they hold up? Unpack the financial logic powering this price call in the full story.
Result: Fair Value of $193.88 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, a sharp drop in bookings for Apex Legends or tougher consumer spending could undermine EA’s outlook and cast doubt on these bullish projections.
Find out about the key risks to this Electronic Arts narrative.
If you see things differently or want to dig into the numbers on your own terms, you can craft your own take in just a few minutes with Do it your way.
A good starting point is our analysis highlighting 1 key reward investors are optimistic about regarding Electronic Arts.
Continue Reading
-
Exploring Valuation as Analyst Optimism Grows Ahead of Upcoming Earnings Release
Expeditors International of Washington (EXPD) has been attracting investor interest because of its record of outperforming earnings estimates over the last two quarters. Analysts are now watching for the next report in early November.
See our latest analysis for Expeditors International of Washington.
Expeditors International’s share price has rebounded in recent weeks, rising 7.4% over the past 90 days and recapturing ground lost earlier this quarter. Despite muted total shareholder return of just 0.8% over the past year, the stock’s three- and five-year total returns remain impressive. This suggests that while near-term momentum is building, long-term investors have still enjoyed strong compounding gains overall.
If strong execution like this has you looking further afield, now is the perfect opportunity to discover fast growing stocks with high insider ownership.
That leaves investors with a key question: Is Expeditors International currently undervalued given its recent momentum and analyst optimism, or has the market already priced in the company’s future growth prospects?
Expeditors International trades at a price-to-earnings (P/E) ratio of 19.1x, notably higher than both the global logistics industry average of 15.7x and its estimated fair P/E of 12x. With shares closing at $119.92, this elevated multiple suggests the market is paying a premium for expected earnings compared to many peers.
The price-to-earnings ratio measures how much investors are willing to pay per dollar of reported earnings. In the logistics sector, it is often used as a gauge of growth or quality relative to industry standards. For Expeditors International, this high P/E could signal that investors expect sustained earnings outperformance or have confidence in the company’s ability to weather industry cycles.
However, when compared to the global logistics average and the estimated fair value multiple for the business, Expeditors International’s premium stands out. This gap may indicate some market over-optimism about future growth, or it could reflect perceived strengths such as high returns on equity and a history of quality earnings. If the market normalizes, valuations could move closer to the fair ratio, so investors should keep that possibility in mind.
Explore the SWS fair ratio for Expeditors International of Washington
Result: Price-to-Earnings of 19.1x (OVERVALUED)
However, slowing revenue growth and negative net income trends could challenge further upside if Expeditors International does not reaccelerate operational performance soon.
Continue Reading
-
Tracking the Changing Narrative for Sabanci Holding After Key Portfolio and Valuation Updates
Haci Ömer Sabanci Holding stock has seen its estimated fair value rise slightly, up from TRY 143.52 to TRY 146.10, even as growth projections have shifted. According to analyst commentary, this modest uptick in the price target reflects the company’s ability to navigate industry conditions and adapt to changing business dynamics. This is despite some adjustments to revenue expectations and discount rates. Stay tuned to discover how investors and analysts are tracking this evolving story and how you can follow ongoing updates to the narrative.
Analyst perspectives on Haci Ömer Sabanci Holding remain largely constructive, with commentary centering on the company’s recent ability to manage industry shifts and deliver operational consistency. While explicit references to this specific company are limited in the current research inputs, the available analyst outlooks provide insights into the types of factors that have influenced street expectations around valuation and future growth.
🐂 Bullish Takeaways
-
Analysts have generally cited strong execution and a focus on cost reductions as key reasons for the resilience seen in adjusted price targets, despite broader industry challenges.
-
The ability to sustain higher gross margins and exhibit ongoing adaptability is being rewarded with modest price target increases. This highlights confidence in management’s operational discipline.
-
Market participants appear to appreciate continued vigilance in navigating complex business conditions, which contributes to the incremental rise in fair value estimates for the stock.
🐻 Bearish Takeaways
-
Some caution remains, with neutral ratings indicating that while execution is solid, upside may already be reflected in the current valuation.
-
Adjustments to revenue expectations and discount rates remain a key reservation as analysts weigh potential near-term risks to growth momentum.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
IBSE:SAHOL Community Fair Values as at Oct 2025 -
Sabanci Holding is considering divesting certain subsidiaries with lower net profit margins and returns on equity. This potential move was highlighted in recent discussions between executives and analysts, according to Reuters.
-
Market observers report that technology retailer Teknosa and food retailer Carrefoursa are among the businesses that may be evaluated for possible divestiture as Sabanci Holding optimizes its portfolio.
-
The company is reportedly reviewing additional subsidiaries to align its business focus and improve overall financial efficiency. This signals a move toward increased strategic selectivity.
Continue Reading
-
